The key is balancing enthusiasm for innovation with commitment to evidence-based practice and patient safety
Daily application of the serum between treatments enhances cumulative improvements
Mechanism of Action Preclinical research suggests that BPC-157 may interact with multiple biological pathways simultaneously
Poster Session II - INTRACRANIAL HEMORRHAGE 02.00 - INTRACRANIAL HEMORRHAGE - 02.01 - INTRACEREBRAL HAEMORRHAGE P772 - ESOC25-965 PREDICTORS OF EARLY PERIHEMORRHAGIC EDEMA EVOLUTION UP TO 72 HOURS IN NON-TRAUMATIC INTRACEREBRAL HEMORRHAGE: A SYSTEMATIC REVIEW AND META-ANALYSIS Madlaine Mller 1,2 , Martina Goeldlin 1 , Bernhard Siepen 1,2 , Mattia Branca 3 , Isabel Hostettler 4 , Janis Rauch 1,2 , Werner Z'graggen 1,5 , Marcel Arnold 1 , Urs Fischer, David Seiffge 1 , Bastian Volbers 1 1 Department of Neurology, Inselspital, Bern University Hospital, Bern, Switzerland, 2 Graduate School for Health Sciences, University of Bern, Bern, Switzerland, 3 Clinical Trials Unit Bern, University of Bern, Bern, Switzerland, 4 Department of Neurosurgery, Cantonal Hospital St
Dialysis is a prohibited method under M1.1, as blood is taken out from the patient and filtered, before being reintroduced back into the patients circulatory system
BPC-157 promotes blood vessel formation (angiogenesis) and cytoprotection, while TB-500 facilitates cell migration and tissue remodeling
